The story of protective humoral immunity against COVID-19 in a chilean cohort of multiple sclerosis patients: Vaccines are necessary

Article Sidebar

18-Sept-5641.pdf
Published Sep 30, 2024
DOI: https://doi.org/10.18103/mra.v12i9.5641

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Lorna Galleguillos
Facultad de Medicina, Universidad del Desarrollo y Departamento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile
Ricardo Alonso
Servicio de Neurología, Hospital Ramos Mejías, Argentina
Andrea Alarcon
Centro de estudios clínicos, Clínica Alemana de Santiago, Chile
Jorge Villacura
Departamento de Neurología y neurocirugía, Clínica Dávila de Santiago, Chile
Marianne Kägi
Departamento de Neurología y neurocirugía, Clínica Dávila de Santiago, Chile
Marianella Hernández
Departamento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile
Violeta Díaz
Departamento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile
Jorge Barahona
Departamento de Neurología y Psiquiatría, Clínica Alemana de Santiago, Chile

Abstract

Background: There is scarce data in Latin America about how the protective humoral immunity behaves in patients that received an inactivated COVID-19 or mRNA vaccine or boosters in people with Multiple Sclerosis (pwMS).


Objective: To evaluate humoral response to COVID-19 vaccines in a cohort of Chilean pwMS treated with high efficacy therapies (HET) and the effect of a booster.


Methods: Observational cohort study of pwMS receiving mRNA or inactivated (CoronaVac) COVID-19 vaccines and a booster with mRNA vaccine 5 months after. IgG anti spike was determined in 4 groups: cladribine, anti-20 (rituximab or ocrelizumab), alemtuzumab and reference group.


Results: Hundred and thirty-two patients: 24.7% on cladribine and 13% on ocrelizumab, 84.9% received CoronaVac.  No significant differences between time from last dose of HET and IgG production. Significant differences on absolute lymphocyte count between cladribine and antiCD20 (p<0.01). Anti-CD20 produced the lowest 4weeks post-vaccine IgG titers. 72.5% pwMS had Protective humoral immunity (PHI) at 4weeks but only 18.5% of the antiCD20 group did have it. The 5 months post-vaccine IgG titers were evaluated in 69 patients; all kept PHI; 26.6% of the antiCD20 group with no previous PHI, received a booster with mRNA vaccine and did produce PHI after it.


Conclusions: CoronaVac produce PHI in pwMS treated with HET in the analyzed cohort, except for Anti-CD20 therapies in our cohort. The booster in the anti CD20 therapy with no PHI after 2 doses of the COVID-19 vaccine had a small impact in the IgG anti spike production. Further studies are needed in our cohort to understand the kinetics of the PHI with inactivated vaccines and the boosters.

Keywords: inactivated vaccine, mRNA vaccine, cladribine, anti-CD20, alemtuzumab, booster

Article Details

How to Cite
GALLEGUILLOS, Lorna et al. The story of protective humoral immunity against COVID-19 in a chilean cohort of multiple sclerosis patients: Vaccines are necessary. Medical Research Archives, [S.l.], v. 12, n. 9, sep. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5641>. Date accessed: 21 nov. 2024. doi: https://doi.org/10.18103/mra.v12i9.5641.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 12 No 9 (2024): Vol 12 No 9 (2024): September ISSUE, Issue 9, VOl.12
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1.- Galleguillos L, Alonso R. Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. Mult Scler Relat Disord. 2021 Sep;54:103142. doi: 10.1016/j.msard.2021.103142. Epub 2021 Jul 16.
2.- Coyle PK, Gocke A, Vignos M et al. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv Ther. 2021 Jul;38(7):3550-3588. doi: 10.1007/s12325-021-01761-3. Epub 2021 Jun 1. Erratum in: Adv Ther. 2022 Jan;39(1):822-830.
3.- Alonso R, Chertcoff A, Leguizamón FDV, Galleguillos Goiry L et al. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211061543.
4.- Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol. 2021 Jul 15;356:577599. doi: 10.1016/j.jneuroim.2021.577599. Epub 2021 May 4.
5.- Achiron A, Dolev M, Menascu S et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler. 2021 May;27(6):864-870. doi: 10.1177/13524585211003476. Epub 2021 Apr 15.
6.- Achiron A, Mandel M, Dreyer-Alster S et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835.
7.- Ministerio de Salud de Chile. Plan nacional de vacunación COVID19. https://www.gob.cl/yomevacuno/ (accessed on April 4th 2022).
8.- Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021 Nov 15;430:120034. doi: 10.1016/j.jns.2021.120034. Epub 2021 Oct 19.
9.- Capone F, Rossi M, Cruciani A, Motolese F, Pilato F, Di Lazzaro V. Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review. Neural Regen Res. 2023 Feb;18(2):284-288. doi: 10.4103/1673-5374.346539. PMID: 35900404; PMCID: PMC9396498.
10.- Pitzalis M, Idda M.L, Lodde V, Loizedda A, Lobina M, Zoledziewska M, Virdis F, Delogu G, Pirinu F, Marini MG, Mingoia M, Frau J, Lorefice L, Fronza M, Carmagnini D, Carta E, Orrù V, Uzzau S, Solla P, et al. (2021) Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in sardinian multiple sclerosis patients. Front Immunol 12:781843.
11.- Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, et al. (2021b) SARS-CoV-2 serology after COVID-19 in multiple sclerosis: an international cohort study. Mult Scler J doi: 10.1177/13524585211035318.
12.- Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R, Evangelou N, George K, Giovannoni G, Godkin A, Grant L, Harding KE, Hibbert A, Ingram G, Jones M, Kang AS, Loveless S, Moat SJ, et al. (2022) COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol 91:89-100.
13.- Georgieva ZG, Dӧffinger R, Kumararatne D, Coles AJ, McCarthy C (2021) Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsingremitting multiple sclerosis patients. Mult Scler doi: 10.1177/13524585211046786.
14.- Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, et al. (2021) Interferon beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Mult Scler Relat Disord 58:103455.
15.- Achtnichts L, Jakopp B, Oberle M, Nedeltchev K, Fux CA, Sellner J, Findling O (2021) Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines 9:1470
16.- Ciotti JR, Valtcheva MV, Cross AH (2020) Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 45:102439.
17.- König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, Nygaard GO (2022) Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol 79:307-309.
18.- Skorić MK, Rogić D, Lapić I, Šegulja D, Habek M (2022) Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod. Mult Scler Relat Disord 57:103435.
19.- Apostolidis SA, Kakara M, Painter MM et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2. Epub 2021 Sep 14.
20.- Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, Levin N, Raposo C, VakninDembinsky A (2021) Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol 78:1510-1514.
21.- Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
22.- Sociedad chilena enfermedades desmielinizantes. https://sochedem.cl/. (accessed on April 4th, 2022)
23.- Elecsys® Anti-SARS-CoV-2. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html. (accessed on April 4th, 2022).
24.- Schiavetti I, Ponzano M, Signori A et al. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult Scler Relat Disord. 2022 Jan;57:103358. doi: 10.1016/j.msard.2021.103358. Epub 2021 Nov 5.
25.- National Multiple Sclerosis Society. Timing MS Medication with COVID-19 vaccines. https://www.nationalmssociety.org/coronavirus-covid-19-information/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines. Accessed on April 4th, 2022.
26.- Disanto G, Sacco R, Bernasconi E et al. Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. JAMA Neurol. 2021 Dec 1;78(12):1529-1531.
27.- Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, Flechter S, Givon U, Guber D, Stern Y, Miron S, Polliack M, Falb R, Sonis P, Gurevich M, Achiron A (2022) COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. J Neurol Sci 434:120155.
28.- Chilimuri S, Mantri N, Gongati S, Zahid M, Sun H (2021) COVID-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. Vaccines 9:219.
29.- Januel E, De Seze J, Vermersch P, Maillart E, Bourre B, Pique J, Moisset X, Bensa C, Maarouf A, Pelletier J, Vukusic S, Audoin B, Louapre C; COVISEP Investigators (2021) Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Mult Scler doi: 10.1177/13524585211049737.
30.- Rose DR, Mahadeen AZ, Carlson AK, Planchon SM, Sedlak J, Husak S, Bermel RA, Cohen JA, Moss BP (2021) Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis. Mult Scler J Exp Transl Clin 7:20552173211057110.